

**MYVLAR- gestodene, ethinyl estradiol tablet**  
**OASIS TRADING**

*Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, [click here](#).*

-----

Gestodene, Ethinyl Estradiol

Oral contraception

Keep out of reach of children

1 tab daily for 21 days; repeat.

Warnings/Precautions:

Smokers over 35yrs of age: not recommended. Uncontrolled hypertension. Hypertriglyceridemia. Discontinue if jaundice, visual disturbances, migraine or other severe headaches occur. Do regular complete physical exams. May need barrier contraception with Sunday starts or postpartum use (see literature). Nursing mothers: not recommended

Contraindications

Thrombophlebitis or thromboembolic disorders. Cerebral vascular or coronary artery disease. Breast or other estrogen-dependent neoplasms. Undiagnosed abnormal genital bleeding. Cholestatic jaundice of pregnancy or jaundice with prior OC use. Hepatic adenoma or carcinoma. Pregnancy (Cat.X).

Interactions

Antagonized by hepatic enzyme inducing drugs (eg, rifampin, griseofulvin, St. John's wort), possibly others. May affect measurement of sex hormone-binding globulin levels

Adverse Reactions:

Hypertension, nausea, vomiting, breakthrough bleeding, amenorrhea, transient delay of ovulation after discontinuation, edema, chloasma, mastodynia, headache, intolerance to contact lenses. Increased risk of gallbladder disease, thromboembolic disorders.

Stearic acid, corn starch, polyethylene glycol 6000

For oral use only

# MYVLAR

## *Drug Facts*

### **Active Ingredients (in one tablet)**

Ethinyl Estradiol 0.03mg

Gestodene 0.075mg

### **Purpose**

Combined oral -  
contraceptive pill

### **Uses**

Oral contraception.

### **Warnings/Precautions:**

Smokers over 35yrs of age: not recommended. Uncontrolled hypertension. Hypertriglyceridemia. Discontinue if jaundice, visual disturbances, migraine or other severe headaches occur. Do regular complete physical exams. May need barrier contraception with Sunday starts or postpartum use (see literature). Nursing mothers: not recommended

### **Contraindications**

Thrombophlebitis or thromboembolic disorders. Cerebral vascular or coronary artery disease. Breast or other estrogen-dependent neoplasms. Undiagnosed abnormal genital bleeding. Cholestatic jaundice of pregnancy or jaundice with prior OC use. Hepatic adenoma or carcinoma. Pregnancy (Cat.X).

### **Interactions**

Antagonized by hepatic enzyme inducing drugs (eg, rifampin, griseofulvin, St. John's wort), possibly others. May affect measurement of sex hormone-binding globulin levels

### **Adverse Reactions:**

Hypertension, nausea, vomiting, breakthrough bleeding, amenorrhea, transient delay of ovulation after discontinuation, edema, chloasma, mastodynia, headache, intolerance to contact lenses. Increased risk of gallbladder disease, thromboembolic disorders.

### **Directions**

1 tab daily for 21 days; repeat.

### **Other Information**

■ Store at room temperature

### **Inactive Ingredient**

Stearic acid, corn starch, polyethylene glycol 6000

### **Questions or comments ?**

Call weekdays from 9 a.m to 5 p.m EST at (201) 669-8405

**Distributed By: P&K FRONTIER MARKETING CORP.**

329 BROAD AVENUE # 2F, PALISADES PARK, NJ 07650, USA

**Made in South Korea**

# MYVLAR

gestodene, ethinyl estradiol tablet

## Product Information

Product Type	HUMAN OTC DRUG	Item Code (Source)	NDC:72689-0012
Route of Administration	ORAL		

## Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
GESTODENE (UNII: 1664P6E6MI) (GESTODENE - UNII:1664P6E6MI)	GESTODENE	0.075 mg
ETHINYL ESTRADIOL (UNII: 423D2T571U) (ETHINYL ESTRADIOL - UNII:423D2T571U)	ETHINYL ESTRADIOL	0.03 mg

## Inactive Ingredients

Ingredient Name	Strength
STEARIC ACID (UNII: 4ELV7Z65AP)	
STARCH, CORN (UNII: O8232NY3SJ)	
POLYETHYLENE GLYCOL 6000 (UNII: 30IQX730WE)	

## Product Characteristics

Color	white	Score	no score
Shape	ROUND	Size	5mm
Flavor		Imprint Code	
Contains			

## Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:72689-0012-1	21 in 1 BLISTER PACK; Type 0: Not a Combination Product	11/22/2018	

## Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
unapproved drug other		11/22/2018	

**Labeler** - OASIS TRADING (689991468)

**Registrant** - OASIS TRADING (689991468)

## Establishment

Name	Address	ID/FEI	Business Operations
OASIS TRADING		689991468	manufacture(72689-0012) , label(72689-0012)

